Policy & Regulation
LegoChem Biosciences partners with Takeda for development of antibody-drug conjugates in immuno-oncology
22 March 2019 -

Biopharmaceutical company LegoChem Biosciences Inc (KOSDAQ:141080) said on Friday that it plans to develop antibody-drug conjugates in immuno-oncology through a research collaboration and license agreement with Takeda Pharmaceutical Company Limited.

This agreement provides Takeda with certain rights to LegoChem Biosciences' antibody-drug conjugate (ADC) technology, ConjuAll, including LCB's proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.

Pursuant to the agreement, Takeda has rights to use the LegoChem Biosciences technology to develop therapeutics directed to up to three undisclosed targets.

Under the terms of the agreement, LegoChem Biosciences Inc will receive USD7.25m in upfront and near-term milestone payments, eligible to receive development, regulatory and commercial milestone payments of up to USD404m as well as royalties on the sales of any resulting ADC products.

LegoChem Biosciences' ConjuAll is a next-generation ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. Its platform provides solutions for site-specific conjugation, linker stability and efficient payload release which are three major unmet needs in ADC development.